BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Particle Sciences Expands Its DOSE(TM) Program With Additional Proprietary Modeling Capabilities


1/4/2012 9:40:36 AM

BETHLEHEM, Pa., Jan. 3, 2012 /PRNewswire/ -- Particle Sciences, a leading drug delivery CRO, has added a third computational module to its DOSE program. The DOSE program uses a combination of empirical data and proprietary modeling tools to efficiently arrive at the optimal drug product for a given API and dosage form. Previously, Particle Sciences implemented software solutions for calculating and predicting solubilization systems for API's and modeling the solubility of a given API in candidate polymers for drug-eluting polymeric devices. A second module introduced in mid-2011 calculates inter-particle forces in dispersed systems, and leads to the design of stable nano or micro particle suspensions. The third and latest addition accurately models the elution of a given API from a non-degrading polymeric device, such as an implant or an intravaginal ring. Based on well-established mathematics and a set of base measurements, this latest addition allows Particle Sciences to significantly reduce the time needed for prototyping drug-device combination products.

According to Dr. Andrew Loxley, Particle Sciences' Director of New Technologies, "These proprietary computational tools, combined with Particle Sciences' industry-leading formulation and process capabilities, give our clients a true competitive advantage, allowing them to get to the right product faster. Particle Sciences has also institutionalized the use of Design of Experiments (DOE) in the product development process. While there is no replacement for actual prototyping and measurement, the systematic use of these modeling tools to guide the DOE approach streamlines our efforts providing our clients with the most expedient path to clinically relevant products."

Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visitwww.particlesciences.com, email info@particlesciences.comor contact us at (610) 861- 4701 for information.

Contact: Maureen Mattera
(610) 861- 4701
mmattera@particlesciences.com

SOURCE Particle Sciences Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES